Gamma Medica-Ideas signs exclusive license and commercialization agreement with Mayo Clinic

September 19, 2015

According to Dr. O'Connor, "Mayo is looking forward to the collaboration with GMI as we work together to bring this advanced technology to the health care industry. We have used GMI's Lumagem technology combined with our inventions to successfully perform close to 2000 patient studies at Mayo over the past four years. We believe that the combination of GMI's detector technology and the algorithms and techniques developed at Mayo, will enable us to achieve a significant reduction in the radiation dose required for molecular breast imaging, and increase the diagnostic utility of this technique."

"Over the past few years the need for secondary imaging in breast cancer diagnosis has become obvious. Until now dedicated breast MRI has been useful in helping fill the void, and the number of MRI secondary breast imaging scans has quickly grown to almost 1 million per year," according to Dr. Patt. "GMI's LumaGEM product in conjunction with the Mayo technology offers accuracy rivaling MRI, with even better specificity and at a fraction of the cost. We are very excited about the possibility of utilizing this technology to deliver improved quality of care in women's health at a lower cost to the healthcare system."

SOURCE: Gamma Medica Ideas, Inc.